Previously, vorapaxar, which is an antagonist of the protease-activated receptor 1 (PAR-1), was believed to be a promising antithrombotic inhibitor with no effect on bleeding.111 However, it was subsequently shown to increase the risk of intracranial haemorrhage.112 Reassuringly, glenzocimab has already been tested in the high-risk setting of stroke treated with thrombolysis, where intracranial haemorrhage is common, and there has been no sign of an increased risk of intracranial haemorrhage with potent GPVI inhibition.24 This evidence concerns the gene F2R and stroke disorder.